Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
07/05/2026 13:33
May 7 (Reuters) - Oragenics Inc OGEN.A: ORAGENICS SIGNS LETTER OF INTENT TO LICENSE CARDIODIALYSIS™ TECHNOLOGY FROM SIGYN THERAPEUTICS TO TARGET TBI-INDUCED SYSTEMIC INFLAMMATION ORAGENICS INC - TO RECEIVE EXCLUSIVE LICENSE FOR CARDIODIALYSIS FOR TBI AND NEURODEGENERATIVE DISEASES ORAGENICS INC - TO PAY 3% ROYALTY ON REVENUE FROM SALES OF LICENSED TECHNOLOGY FOR SIX YEARS AFTER FDA CLEARANCE ORAGENICS INC - TO ISSUE 3.25 MILLION RESTRICTED PREFERRED SHARES TO SIGYN, CONVERTIBLE ONE-TO-ONE Source text: ID:nGNX8tYPnn Further company coverage: OGEN.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sigyn Therapeutics
See all newsBrief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Sigyn Therapeutics Appoints Ajay Verma To Its Scientific Advisory Board
Brief: Reign Sapphire Corp. Provides Shareholder Update And Expectations For 2018
Brief: Reign Sapphire Says Expects To Release Reign Coin's White Paper Later This Month
Brief: Reign Sapphire Corporation signs binding letter of intent to acquire 100% of the assets of custom jewelry company Coordinates Collection Inc